Lineage Cell (Israel) Probability of Future Stock Price Finishing Under 107.44
| LCTX Stock | ILA 195.80 32.10 14.09% |
Lineage |
Lineage Cell Target Price Odds to finish below 107.44
The tendency of Lineage Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to 107.44 or more in 90 days |
| 195.80 | 90 days | 107.44 | near 1 |
Based on a normal probability distribution, the odds of Lineage Cell to drop to 107.44 or more in 90 days from now is near 1 (This Lineage Cell Therapeutics, probability density function shows the probability of Lineage Stock to fall within a particular range of prices over 90 days) . Probability of Lineage Cell Therape price to stay between 107.44 and its current price of 195.8 at the end of the 90-day period is near 1 .
Assuming the 90 days trading horizon the stock has the beta coefficient of 95.0 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Lineage Cell will likely underperform. In addition to that Lineage Cell Therapeutics, has an alpha of 102.7483, implying that it can generate a 102.75 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Lineage Cell Price Density |
| Price |
Predictive Modules for Lineage Cell
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lineage Cell Therape. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Lineage Cell Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Lineage Cell is not an exception. The market had few large corrections towards the Lineage Cell's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lineage Cell Therapeutics,, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lineage Cell within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 102.75 | |
β | Beta against Dow Jones | 95.00 | |
σ | Overall volatility | 48.65 | |
Ir | Information ratio | 0.12 |
Lineage Cell Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lineage Cell for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lineage Cell Therape can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Lineage Cell Therape is way too risky over 90 days horizon | |
| Lineage Cell Therape appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 1.83 M. Net Loss for the year was (11.93 M) with profit before overhead, payroll, taxes, and interest of 1.44 M. | |
| Lineage Cell Therapeutics, has accumulated about 68.75 M in cash with (23.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. |
Lineage Cell Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lineage Stock often depends not only on the future outlook of the current and potential Lineage Cell's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lineage Cell's indicators that are reflective of the short sentiment are summarized in the table below.
| Float Shares | 126.29M | |
| Average Daily Volume Last 10 Day | 167.87k | |
| Average Daily Volume In Three Month | 167.87k |
Lineage Cell Technical Analysis
Lineage Cell's future price can be derived by breaking down and analyzing its technical indicators over time. Lineage Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Lineage Cell Therapeutics,. In general, you should focus on analyzing Lineage Stock price patterns and their correlations with different microeconomic environments and drivers.
Lineage Cell Predictive Forecast Models
Lineage Cell's time-series forecasting models is one of many Lineage Cell's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Lineage Cell's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Lineage Cell Therape
Checking the ongoing alerts about Lineage Cell for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Lineage Cell Therape help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Lineage Cell Therape is way too risky over 90 days horizon | |
| Lineage Cell Therape appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 1.83 M. Net Loss for the year was (11.93 M) with profit before overhead, payroll, taxes, and interest of 1.44 M. | |
| Lineage Cell Therapeutics, has accumulated about 68.75 M in cash with (23.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. |
Other Information on Investing in Lineage Stock
Lineage Cell financial ratios help investors to determine whether Lineage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lineage with respect to the benefits of owning Lineage Cell security.